Myristyl aspartic acid | 70051-97-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Myristyl aspartic acid
• 英文别名: (2S)-2-(tetradecylamino)butanedioic acid
• CAS: 70051-97-7
• 化学式: C₁₈H₃₅NO₄
• 分子量: 329.5
• InChiKey: PFFBGOKORITACC-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Methods for reducing the side effects associated with mirtzapine treatment
  申请人：Rao Srinivas

  公开号：US20060122127A1

  公开（公告）日：2006-06-08

  Compositions, and methods of use thereof, are provided for the prevention or treatment of side effects associated with the use of drugs that act as 5HT2/5HT3 serotonin receptor antagonists and alpha-2 adrenergic receptor antagonists (5HT2/5HT3 antagonist/alpha-2 antagonist). The method involves using dopamine-releasing compounds, such as amantadine, anticonvulsants, such as zonisamide, or dopamine/norepinephrine reuptake inhibitors, such as bupropion, in combination with 5HT2/5HT3 antagonist/alpha-2 antagonists, such as mirtazapine, to reduce the excessive daytime drowsiness and/or weight gain associated with 5HT2/5HT3 antagonist/alpha-2 antagonist use for the treatment of disorders, such as, depression, schizophrenia, anxiety disorders, sleep-related breathing disorders, insomnia, migraine headache, chronic tension-type headache, hot flashes, lower back pain, neuropathic pain and functional somatic syndromes. Formulations of dopamine-releasing compounds or anticonvulsants with 5HT2/5HT3 antagonist/alpha-2 antagonists are provided. In particular embodiments, combination therapy with mirtazapine and zonisamide provides relief from chronic low back pain, while reducing or avoiding side effects associated with monotherapy with mirtazapine or zonisamide.
• Absorbable biocompatible materials
  申请人：Luthra K. Ajay

  公开号：US20060134166A1

  公开（公告）日：2006-06-22

  Biocompatible carrier materials are described herein for enhanced delivery of therapeutic agents. Embodiments include materials and methods for making a biodegradable coating on a surface of a medical device by forming a biodegradable layer on at least a portion of the surface of the medical device, the layer comprising a copolymer and a therapeutic agent releasable into a patient after implantation of the device into the patient, wherein the copolymer is a polyamino acid derivatized to have a hydrophobic hydrocarbon side chain that has a molecular weight from about 14 to about 5000. One embodiment is a polypeptide that includes at least one amino acid that has been modified to include a hydrophobic side chain. The number and type of amino acids and hydrophobic side chains may be altered to adjust the solubility of the material in solvents, and to control the hydrophobic-to-hydrophilic balance of the coatings made with the materials, so as to enhance therapeutic agent delivery. And hydrophilic groups may also be introduced as a further means to adjust the material's property.